

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

NEOMAY 500 000 IU/g powder for use in drinking water/milk replacer

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g contains:

Active substance:

Neomycin (as neomycin sulphate) 500 000 IU

Excipients:

Qualitative composition of excipients and other constituents

<i>Lactose monohydrate</i>

Powder for use in drinking water/milk replacer.
White or almost white powder.

3. CLINICAL INFORMATION

3.1 Target species

Cattle (calves), pig (weaned and fattening pigs), chicken (including laying hens), duck, turkey (including turkey hens), goose, quail and partridge.

3.2 Indications for use for each target species

For treatment of gastrointestinal infections caused by *E. coli* susceptible to neomycin.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance, to aminoglycosides or to any of the excipients.

Do not use in cases of intestinal obstruction.

3.4 Special warnings

Medicated drinking water intake can be affected by the severity of the disease. In case of insufficient intake of water/milk replacer, calves and pigs should be treated parenterally.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Powder for oral solution that is to be dissolved in water and cannot be used as it is. Special care should be taken when considering administration of the veterinary medicinal product to the newborn calf due to the known higher gastrointestinal absorption of neomycin in neonates. This higher absorption could lead to an increased risk of oto- and nephrotoxicity. The use of the veterinary medicinal product in neonates should be based on the benefit/risk determination from the attending veterinarian.

Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to neomycin and may decrease the effectiveness of treatment with aminoglycosides due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to aminoglycosides should avoid contact with the veterinary medicinal product.
Wash hands after use.

In case of accidental spillage onto skin, seek medical advice immediately and show the package leaflet or the label to the physician. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the immediate packaging for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy, lactation or lay in the target species.

Pregnancy, lactation and laying birds:

Use only according to the benefit-risk assessment by the responsible veterinarian. Laboratory studies in animals have not produced any evidence of teratogenic effects of neomycin.

3.8 Interaction with other medicinal products and other forms of interaction

General anaesthetics and muscle relaxing products increase the neuro-blocking effect of aminoglycosides. This may cause paralysis and apnoea. Special care should be taken when using concurrently with diuretics and potentially oto- or nephrotoxic substances.

3.9 Administration routes and dosage

In drinking water/milk replacer use.
25 000 IU of neomycin per kg bodyweight per day for 3 to 4 consecutive days, corresponding to 5 g of veterinary medicinal product per 100 kg bodyweight per day for 3 to 4 days.

Based on the recommended dose and the number and weight of animals to be treated, the exact daily concentration of the veterinary medicinal product should be calculated according to the following formula:

$$\begin{array}{l} \text{g of veterinary medicinal product} \\ \text{per l of drinking water/milk replacer} \end{array} = \frac{\text{g of product/kg bodyweight day} \times \text{average bodyweight (kg) of} \\ \text{animals to be treated}}{\text{Average daily water/milk replacer intake (l/} \\ \text{animal)}}$$

To ensure a correct dosage body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

The intake of medicated water depends on the clinical condition of the animals. In order to obtain the correct dosage the concentration of neomycin may need to be adjusted accordingly.

The maximum solubility of the powder is 255 000 IU of neomycin/ml (510 g of veterinary medicinal product/L) of water.

For the administration of the veterinary medicinal product commercially available dosing pumps can be used.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Nephrotoxic and/or ototoxic effects may occur in case of accidental overdose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle (Calves).

Meat and offal: 14 days.

Pigs (weaned and fattening pigs)

Meat and offal: 3 days

Chickens (including laying hens), ducks, turkeys, turkey hen, goose, quail and partridge.

Meat and offal: 14 days.

Eggs: zero days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

ATCvet code: QA07AA01.

4.2 Pharmacodynamics

Neomycin is an antibiotic from the aminoglycoside family. Aminoglycosides have a broad antibacterial spectrum with good activity against Gram negative species, especially *Escherichia coli* and less activity against Gram positive species. This class of antimicrobials has no effect against anaerobic bacteria.

Neomycin binds to the 30S subunit of the bacterial ribosome which disturbs the reading of the constituent code of the RNA messenger, and finally the synthesis bacterial protein. At high concentrations, it has been shown that aminoglycosides damage the cell wall, conferring bactericidal and bacteriostatic properties.

The resistance mechanisms are complex and differ between aminoglycoside molecules. Four mechanisms of resistance have been identified: changes of the ribosome, reduction of permeability, inactivation by enzymes and substitution of the molecular target. The common mechanism of resistance is the production of aminoglycoside modifying enzymes. These resistance mechanisms can be located in mobile genetics elements increasing the likelihood of spread of aminoglycoside resistance as well as co and cross-resistance. The level of resistance of pathogenic *E. coli* towards neomycin in calves in Europe ranges between 20 and 50 %.

4.3 Pharmacokinetics

Neomycin is poorly absorbed from the gastrointestinal tract. Absorption from the gastrointestinal tract can be significant in neonates. 90% of neomycin is excreted in the faeces after oral administration.

Environmental properties

The active ingredient, neomycin sulfate, is persistent in the environment.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

No information is available on potential interactions or incompatibilities of this veterinary medicinal product administered orally by mixing into drinking water containing biocidal products, feed additives or other substances used in drinking water.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 6 months.

Shelf life after dilution in drinking water according to directions: 24 hours.

Shelf life after dilution in milk replacer according to directions: use immediately.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Bags composed of a triple complex film formed by a polyester film, an aluminum film and a sheet of low density polyethylene joined by a polyurethane base adhesive, closed by thermal system.

Pack size: bag of 100 g and 1 kg.

Not all pack sizes may be marketed

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Laboratorios Maymo, S.A.U.

7. MARKETING AUTHORISATION NUMBER

Vm 42204/4001

8. DATE OF FIRST AUTHORISATION

09 January 2017

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

March 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 24 July 2025